首页> 外国专利> Administration of enoxoparin sodium to patients 75 years and older with ST-segment elevation myocardial infarction

Administration of enoxoparin sodium to patients 75 years and older with ST-segment elevation myocardial infarction

机译:依诺肝素钠用于75岁及以上ST段抬高型心肌梗死的患者

摘要

Methods for treating ST-segment elevation myocardial infarction in a human patient 75 years of age or older. The methods comprise administering a dose of less than 1 mg per kg body weight, about 0.75 mg per kg of body weight, or 0.75 mg per kg of body weight of enoxaparin sodium by subcutaneous injection approximately every twelve hours for a therapeutic dosing period. The methods may include fibrinolytic therapy. The treatment methods may be used to prevent one or more of, mortality, myocardial re-infarction, myocardial ischemia, stroke, or severe congestive heart failure. Articles of manufacture for use in connection with treating ST-segment elevation myocardial infarction in a human patient 75 years of age or older are also disclosed. The articles of manufacture comprise enoxaparin sodium, and instructions designed to achieve administration to a patient of a dose of less than 1 mg per kg body weight, about 0.75 mg per kg of body weight, or 0.75 mg per kg of body weight of enoxaparin sodium, by subcutaneous injection approximately every twelve hours for a therapeutic dosing period.
机译:在75岁或以上的人类患者中治疗ST段抬高型心肌梗死的方法。该方法包括大约每十二小时通过皮下注射施用小于1mg / kg体重,小于约0.75mg / kg体重或0.75mg / kg体重的依诺肝素钠剂量,用于治疗给药期。该方法可以包括纤维蛋白溶解疗法。该治疗方法可用于预防死亡率,心肌再梗塞,心肌缺血,中风或严重充血性心力衰竭中的一种或多种。还公开了与在75岁或以上的人类患者中治疗ST段抬高型心肌梗死有关的制品。所述制品包含依诺肝素钠,以及旨在向患者施用小于1 mg / kg体重,约0.75 mg / kg体重或0.75 mg / kg依诺肝素钠的剂量的说明书大约每十二小时通过皮下注射进行治疗,并持续给药。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号